Navigation Links
Results From IMPROVE Study Show Therapeutic Effect of New Formulation of Rebif(R) at 16 Weeks in Patients With Multiple Sclerosis
Date:9/21/2008

ts treated with the new formulation of Rebif(R) had zero combined unique active brain lesions at week 16, compared to only 16.7% in the placebo group.

Results for the secondary and tertiary endpoints of the IMPROVE study will be available at the end of the 40-week treatment period.

The safety profile of the new formulation of Rebif(R) reported in this study is consistent with the known safety profile of Rebif(R). No unexpected safety concerns were identified in this study.

The new formulation of Rebif(R) was approved in the European Union in August 2007 and in Canada in September 2007. It is now marketed in all EU countries and in Canada. The new formulation of Rebif(R) is not available in the United States.

About Rebif(R)

Rebif(R) (interferon beta-1a) is a disease-modifying drug used to treat relapsing forms of multiple sclerosis (MS) and is similar to the interferon beta protein produced by the human body. The efficacy of Rebif(R) in chronic progressive MS has not been established. Interferons are thought to help modulate the body's immune system and reduce inflammation. The exact mechanism is unknown.

Rebif(R), which was approved in Europe in 1998 and in the US in 2002, is registered in more than 80 countries worldwide. Rebif(R) has been proven to delay the progression of disability, reduce the frequency of relapses and reduce MRI lesion activity and area.* Rebif(R) is available in a 22 micrograms and 44 micrograms ready-to-use pre-filled syringe and a titration pack (8.8 micrograms).

Rebif(R) should be used with caution in patients with a history of depression, liver disease and seizures. Most commonly reported side effects are flu-like symptoms, injection site disorders, elevation of liver enzymes and blood cell abnormalities. Patients, especially those with depression, seizure disorders, or liver problems, should discuss treatment with Rebif(R) with their doctors. For more information about Rebif(R), please visi
'/>"/>

SOURCE Merck Serono
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. Haemacure Reports Third Quarter 2007 Results
2. Brooke Franchise Corporation Announces Selected July Results
3. AKELA Pharma Inc. announces positive results for the extension part of its Phase IIb Fentanyl TAIFUN(R) trial
4. Somanetics Corporation to Release Third Quarter 2007 Financial Results and Host Conference Call September 19
5. The New England Journal of Medicine Publishes EURIDIS/ADONIS Study Results Showing Dronedarone Maintained Sinus Rhythm in Patients With Atrial Fibrillation or Flutter With no Observed Pro-Arrhythmia
6. NBTY Announces Preliminary Unaudited Net Sales Results For August 2007
7. Martek Announces Third Quarter 2007 Financial Results
8. MDS Reports Third Quarter 2007 Results
9. Authentidate Holding Corp. to Report Fourth Quarter and Fiscal 2007 Year End Results on Thursday, September 13, 2007
10. Robbins & Myers to Release Fourth Quarter and 2007 Fiscal Year Results on Monday, October 15, 2007
11. NMHC Reports Fourth Quarter and Fiscal Year 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... strongly associated with Alzheimer,s disease; however, researchers are still ... causal agent of the onset and development of the ... beta-amyloid is not harmful when found in isolation but ... to form the so-called amyloid fibrils , "We are ... with multiple ones because each aggregate of peptide, which ...
(Date:10/1/2014)... 1, 2014 Patients with increased inflammation, including ... greatly increased risk of depression. For example, a ... hepatitis C virus infection causes depression in approximately ... more commonly known as fish oil, have a ... risk of heart disease and reducing triglyceride levels. ...
(Date:10/1/2014)... October 01, 2014 Insuranceragents.info has ... a good life insurance plan for vulnerable family members. ... vulnerable family members. Providers in the family should always ... cause financial hardships for the rest of the family. ... policies. Families can benefit more from temporary coverage or ...
(Date:10/1/2014)... ATLANTA (PRWEB) October 01, 2014 ... executive networking and relationship-marketing firm, announced today ... Security Executive® and Project of the Year ... decision makers representing organizations in financial services, ... include large-scale technology endeavors that address key ...
(Date:10/1/2014)... 01, 2014 Between 23 million and ... U.S., according to figures from the National Institutes of ... (AARDA), and many of them have something else in ... undiagnosed celiac disease. Gluten Free Therapeutics, makers of ... undiagnosed celiac disease by publishing a series of blog ...
Breaking Medicine News(10 mins):Health News:Laying siege to beta-amyloid, the key protein in Alzheimer's disease 2Health News:Omega-3 fatty acids may prevent some forms of depression 2Health News:Life Insurance for Families - Clients Can Compare Affordable Rates Online! 2Health News:T.E.N. Announces Nominees for the 2014 ISE® North America Awards; People’s Choice Award voting now open to industry at large 2Health News:T.E.N. Announces Nominees for the 2014 ISE® North America Awards; People’s Choice Award voting now open to industry at large 3Health News:T.E.N. Announces Nominees for the 2014 ISE® North America Awards; People’s Choice Award voting now open to industry at large 4Health News:T.E.N. Announces Nominees for the 2014 ISE® North America Awards; People’s Choice Award voting now open to industry at large 5Health News:T.E.N. Announces Nominees for the 2014 ISE® North America Awards; People’s Choice Award voting now open to industry at large 6Health News:T.E.N. Announces Nominees for the 2014 ISE® North America Awards; People’s Choice Award voting now open to industry at large 7Health News:Informative New Blog Series Underscores Link Between Celiac Disease and Other Autoimmune Disorders 2Health News:Informative New Blog Series Underscores Link Between Celiac Disease and Other Autoimmune Disorders 3
... , , , ... BMR ), The Leading Provider of Real Estate to the Life Science ... ring The Closing Bell(R) at the New York Stock Exchange on Thursday, ... anniversary of the company,s initial public offering. The ceremony will take place ...
... Tinnitus Sufferer ... ... of a deep-sleep to a high pitch ringing sound in your ear, or constantly hearing ... reality for millions of men and women who suffer from the medical condition tinnitus, often ...
... ... marketplace. , ... FL (PRWEB) August 6, 2009 -- Because prices and benefits for Medicare Supplement (Medigap) ... rates offered by GetOnlineQuotes.com are an affordable and viable option for those 65 and ...
... August 6, 2009 Comprehensive health reform proposals now before ... young adults ages 19-29 gain coverage, and such reforms ... coverage would not lose it, according to a new ... Americans through expansions in Medicaid and a health insurance ...
... Addison, TEXAS, Aug. 5 U L URU ... today announced that it has scheduled a conference call to discuss the second ... on Monday, August 17, 2009 at 9:00 a.m. Eastern Time. , , ... international callers dial (850) 429-1388 (access code 23453#) five to ten minutes prior ...
... , , MENLO PARK, Calif., ... announced that it has provided written notice to The NASDAQ Stock ... stock from the NASDAQ Global Market. The Company currently anticipates that, ... the Securities and Exchange Commission and NASDAQ a Form 25 relating ...
Cached Medicine News:Health News:BioMed Realty Trust Commemorates Five-Year Anniversary as a Public Company 2Health News:BioMed Realty Trust Commemorates Five-Year Anniversary as a Public Company 3Health News:BioMed Realty Trust Commemorates Five-Year Anniversary as a Public Company 4Health News:BioMed Realty Trust Commemorates Five-Year Anniversary as a Public Company 5Health News:BioMed Realty Trust Commemorates Five-Year Anniversary as a Public Company 6Health News:BioMed Realty Trust Commemorates Five-Year Anniversary as a Public Company 7Health News:Lipo-Flavonoid Launches New Video Testimonial 2Health News:Lipo-Flavonoid Launches New Video Testimonial 3Health News:GetOnlineQuotes.com to Offer AARP/United Healthcare Medicare Supplement Insurance to Florida Residents 2Health News:Health reform proposals could help 13 million uninsured young adults gain coverage 2Health News:Health reform proposals could help 13 million uninsured young adults gain coverage 3Health News:ULURU Inc. Announces Conference Call to Discuss Financial Results for the Second Quarter Ended June 30, 2009 and to Provide a Business Update 2Health News:XTENT Announces Plan for NASDAQ Delisting and Filing of Certificate of Dissolution 2
(Date:10/1/2014)... and NOTTINGHAM, England , ... CBRX ) today announced that its subsidiary, Molecular ... Clinical Trials platform at the annual CPhI/ICSE Worldwide event ... aims to support companies with the rapid development of ... new enabling technologies screening platform, which incorporates the company,s ...
(Date:10/1/2014)... and NEW YORK , October 1, ... Research Organization (CRO) and service provider for the medical industries, announced ... of offices in New York City . genae ... City is strategically centered in one of the highest ... Coast", said Philippe Kassab , President at genae Americas. "The ...
(Date:10/1/2014)... 1, 2014 Trovagene, Inc., (NASDAQ:  TROV) ... that Eli Diamond , MD, Assistant Attending ... presented clinical data from an ongoing study demonstrating ... for the determination of oncogene mutational status in ... results were presented to both treating physicians and ...
Breaking Medicine Technology:Columbia Laboratories' UK Subsidiary To Launch New Development Platform At CPHI 2Columbia Laboratories' UK Subsidiary To Launch New Development Platform At CPHI 3genae Opens Offices in New York City 2Clinical Performance of Trovagene's Precision Cancer Monitoring Platform Presented at Second Annual International ECD Medical Symposium 2Clinical Performance of Trovagene's Precision Cancer Monitoring Platform Presented at Second Annual International ECD Medical Symposium 3Clinical Performance of Trovagene's Precision Cancer Monitoring Platform Presented at Second Annual International ECD Medical Symposium 4
... Roper Industries, Inc. (NYSE: ROP ) ... (CUSIP No. 776696AA4) (the "Notes") will accrue contingent interest for ... at an annual rate of 0.25% of the average market ... January 12, 2011. Contingent cash interest, which the Company has ...
... 18, 2011 Soligenix, Inc. (Soligenix or the ... a late-stage biopharmaceutical company, announced today promising preliminary ... beclomathasone dipropionate or BDP) in a canine gastrointestinal ... that dogs treated with SGX202 demonstrated statistically significant (p=0.04) ...
Cached Medicine Technology:Soligenix Announces Positive Preliminary Results of SGX202 in Radiation Injury 2Soligenix Announces Positive Preliminary Results of SGX202 in Radiation Injury 3Soligenix Announces Positive Preliminary Results of SGX202 in Radiation Injury 4Soligenix Announces Positive Preliminary Results of SGX202 in Radiation Injury 5
BB Watchmaker Forceps, Pakistan, 4.5" fine point....
The vertebral body replacement (VBR) is used for the anterior thoracic and lumbar spine. It is intended for use in the thoracic and lumbar spine to replace a collapsed, damaged, or unstable vertebral...
Vertigraft femoral shaft an large femoral cross-section designed primarily for use in lumbar corpectomy procedures. Freeze dried preservation....
... system provides anterior column support for single ... T1 to L5. The system consists of ... cages that are stacked to a desired ... Carbon fiber reinforced polymer material emulates the ...
Medicine Products: